Form 4: SpringWorks Therapeutics COO Receives Stock Options and Restricted Stock Units

SpringWorks Therapeutics' Chief Operating Officer, Badreddin Edris, was granted stock options and restricted stock units on January 10, 2025.

Summary

• Badreddin Edris, the Chief Operating Officer of SpringWorks Therapeutics, received a grant of 27,023 restricted stock units (RSUs) on January 10, 2025.
• These RSUs will vest in three tranches: 33% on January 10, 2026, 33% on January 10, 2027, and the remaining 34% on January 10, 2028, contingent on continued service.
• Additionally, Mr. Edris was granted stock options to purchase 78,960 shares of common stock at an exercise price of $43 per share.
• These options will vest in 48 equal monthly installments starting after January 10, 2025, also subject to continued service.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of equity compensation, which is generally positive for aligning management interests with shareholders. There are no negative implications.

Positives

• The grant of RSUs and stock options aligns the COO's interests with the long-term success of the company.
• The vesting schedules for both the RSUs and stock options encourage continued service and commitment from the COO.

Risks

• The value of the stock options is dependent on the future performance of the company's stock price.
• The vesting of both RSUs and stock options is contingent on the COO's continued employment with the company.

Future Outlook

The vesting of the RSUs and stock options is contingent on the continued service of the COO, indicating a focus on long-term commitment.

Industry Context

Equity compensation is a common practice in the biotechnology industry to attract and retain key executives.

Comparison to Industry Standards

• Stock options and restricted stock units are standard forms of equity compensation for executives in the biotech industry.
• Vesting schedules are typically structured to incentivize long-term performance and retention, similar to what is seen in this document.
• The specific amounts and vesting terms may vary based on company size, stage, and individual executive roles, but the general structure is consistent with industry norms.

Stakeholder Impact

• The equity grants align the COO's interests with those of shareholders, potentially leading to increased focus on long-term value creation.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, restricted stock units, RSUs, equity compensation, executive compensation, SpringWorks Therapeutics, SWTX, Badreddin Edris